Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Noha, Lim"'
Autor:
Carolyn H. Baloh, MD, Noha Lim, Michelle Huffaker, Pooja Patel, Jody Tversky, George Du Toit, MB, BCh, Gideon Lack, MB, BCh, Tanya M. Laidlaw, Donald W. MacGlashan
Publikováno v:
World Allergy Organization Journal, Vol 17, Iss 8, Pp 100940- (2024)
Antigen-specific IgG2 and IgG3 are rarely measured in food allergy clinical trials despite known function in preventing mast cell and basophil activation. Our objective was to determine whether measuring peanut-specific IgG2 and IgG3 levels would cor
Externí odkaz:
https://doaj.org/article/ef11928c1bdf4be4a4603d24b9ca3e0f
Autor:
Qian Xiao, Joseph Mears, Aparna Nathan, Kazuyoshi Ishigaki, Yuriy Baglaenko, Noha Lim, Laura A. Cooney, Kristina M. Harris, Mark S. Anderson, David A. Fox, Dawn E. Smilek, James G. Krueger, Soumya Raychaudhuri
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Psoriasis is a chronic, systemic inflammatory condition primarily affecting skin. While the role of the immune compartment (e.g., T cells) is well established, the changes in the skin compartment are more poorly understood. Using longitudina
Externí odkaz:
https://doaj.org/article/dbc9e298d8244b0593bbd1a55d0a25b0
Autor:
Kasia Owczarczyk, Matthew D. Cascino, Cecile Holweg, Gaik W. Tew, Ward Ortmann, Timothy Behrens, Thomas Schindler, Carol A. Langford, E. William St. Clair, Peter A. Merkel, Robert Spiera, Philip Seo, Cees G.M. Kallenberg, Ulrich Specks, Noha Lim, John Stone, Paul Brunetta, Marco Prunotto, the RAVE-ITN Research Group
Publikováno v:
JCI Insight, Vol 5, Iss 18 (2020)
BACKGROUND Baseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical respons
Externí odkaz:
https://doaj.org/article/b7bd1818f0e642e5849a9f696ba49b07
Autor:
Qian Xiao, Joseph Mears, Aparna Nathan, Kazuyoshi Ishigaki, Yuriy Baglaenko, Noha Lim, Laura A. Cooney, Kristina M. Harris, Mark Anderson, David A. Fox, Dawn E. Smilek, James G. Krueger, Soumya Raychaudhuri
BackgroundPsoriasis is a chronic, systemic inflammatory condition, primarily affecting skin and joints. It is an immune-mediated disease driven by IL-17-producing T cells in the skin. However, epidermal cells such as keratinocytes are now also recogn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9520b950789c6f67f315dc891e29cbf9
https://doi.org/10.1101/2022.10.14.22281091
https://doi.org/10.1101/2022.10.14.22281091
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Autoimmunity represents a broad category of diseases that involve a variety of organ targets and distinct autoantigens. For patients with autoimmune diseases who fail to respond to approved disease-modifying treatments, autologous hematopoietic stem
Externí odkaz:
https://doaj.org/article/f1a9483772774ecf9c4c2da0e2eda2bf
Autor:
Johanna M. Smeekens, Carolyn Baloh, Noha Lim, David Larson, Tielin Qin, Lisa Wheatley, Edwin H. Kim, Stacie M. Jones, A. Wesley Burks, Michael D. Kulis
Publikováno v:
The journal of allergy and clinical immunology. In practice. 10(12)
Antigen-specific immunoglobulin responses have yet to be studied at the oral mucosal surface during peanut oral immunotherapy (PnOIT).We aimed to quantify salivary peanut-specific IgG4 (PNsIgG4) and IgA (PNsIgA) and total IgG4 and IgA in participants
Autor:
Gabriele Gamerith, Finn Mildner, Peter A Merkel, Kristina Harris, Laura Cooney, Noha Lim, Robert Spiera, Philip Seo, Carol A Langford, Gary S Hoffman, E William St Clair, Fernando C Fervenza, Paul Monach, Steven R Ytterberg, Duvuru Geetha, Arno Amann, Dominik Wolf, Ulrich Specks, John H Stone, Andreas Kronbichler
Publikováno v:
Annals of the rheumatic diseases.
ObjectivesWe investigated whether soluble immune checkpoints (sICPs) predict treatment resistance, relapse and infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).MethodsPlasma sICP concentrations from ava
Autor:
Emily K, Sims, Brian N, Bundy, Kenneth, Stier, Elisavet, Serti, Noha, Lim, S Alice, Long, Susan M, Geyer, Antoinette, Moran, Carla J, Greenbaum, Carmella, Evans-Molina, Kevan C, Herold, Anette-Gabriele, Ziegler
Publikováno v:
Sci Transl Med
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a previously reported randomized controlled trial of nondiabetic relatives at high risk for type 1 diabetes (T1D).
Autor:
Stephen E Gitelman, Brian N Bundy, Ele Ferrannini, Noha Lim, J Lori Blanchfield, Linda A DiMeglio, Eric I Felner, Jason L Gaglia, Peter A Gottlieb, S Alice Long, Andrea Mari, Raghavendra G Mirmira, Philip Raskin, Srinath Sanda, Eva Tsalikian, John M Wentworth, Steven M Willi, Jeffrey P Krischer, Jeffrey A Bluestone, Mayalin Barr, Jeanne Buchanan, Joanne Cabbage, Peter Coleman, Monica De La Vega, Carmella Evans-Molina, Christine Ferrara, Felicity Healy, Laurie Higgins, Megan Hildinger, Margaret Jenkins, Nora Kayton Bryant, Amanda Kinderman, Nisha Koshy, Brianne Kost, Suzanne Krishfield, Olena Kucheruk, Karen Lindsley, Manasa Mantravadi, Shelley Mesfin, Aaron Michels, Mary Ellen Migre, Pantea Minnock, Elham Mohammed-Nur, Jennifer Nelson, Ashvin Nursing, Ryan O'Donnell, Diana Olivos, Melissa Parker, Leanne Redl, Nicole Reed, Brittany Resnick, Peter Sayre, Elisavet Serti, Emily Sims, Karen Smith, Carol Soppe, Fiona Stuart, Sarah Szubowicz, Michel Tansey, Jennifer Terrell, Sarah Tersey, Christine Torok, Kelly Watson, Rebecca Wesch, Steven Willi, Stephanie Woerner
Publikováno v:
Lancet Diabetes Endocrinol
Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim
Autor:
Eva Tsalikian, Andrea Mari, Jeffrey A. Bluestone, Srinath Sanda, Peter A. Gottlieb, Steven M. Willi, Philip Raskin, S. Alice Long, Ele Ferrannini, Noha Lim, Jason L. Gaglia, John M. Wentworth, Linda A. DiMeglio, Jeffrey P. Krischer, Gleevec Study Team, Eric I. Felner, Stephen E. Gitelman, Raghavendra G. Mirmira, J Lori Blanchfield, Brian N. Bundy
Publikováno v:
SSRN Electronic Journal.
Background: Type 1 diabetes results from autoimmune-mediated destruction of beta cells. The tyrosine kinase inhibitor imatinib may impact relevant immunologic and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes